ExeVir Bio, a biotech company developing heavy chain-only antibodies, has appointed Michael Garrett as its new CEO, effective 1 December 2024. He will also join ExeVir’s Board of Directors. Garrett has more…
Belgium: Garrett appointed as CEO at ExeVir Bio
…
…






